Tag: Albert Bourla
Pfizer gets PAXLOVID FDA approval for COVID-19 in high-risk adults
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the US Food and Drug Administration (FDA) to ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five
Pfizer and BioNTech have received the US Food and Drug Administration (FDA) emergency use authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine for children ... Read More
Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn
Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to ... Read More
Pfizer and BioNTech secure FDA EUA for BNT162b2 Covid-19 vaccine
BNT162b2 FDA EUA : Pfizer and BioNTech have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for BNT162b2, their ... Read More
UK authorizes Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine
The UK has given a temporary authorization for emergency use for the BNT162b2 Covid-19 vaccine candidate developed by Pfizer and BioNTech. The emergency use authorization ... Read More
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech
Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in ... Read More
Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir
Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter's investigational antiviral remdesivir for the treatment of Covid-19. Under the ... Read More